Medtronic, Inc. has announced FDA approval for company’s iPro2, Professional Continuous Glucose Monitoring (CGM) system. The iPro2 has been previously covered on Medgadget . The system comprises a wearable continuous glucose monitoring sensor/data logger and docking station for uploading the recorded data. The technology is tailored for healthcare providers looking to monitor and retrospectively review their patients’ glucose management. The assessments are carried out over a three day period and can help the 
clinician identify excursions from optimal glucose levels and adjust the patient’s glucose management plan accordingly.
The press release explains the operation of the system:
Setup can be completed in a few minutes and includes inserting a glucose sensor into the patient’s skin, educating the patient, and connecting the iPro2 to the sensor. The patient then conducts normal daily activities while the iPro2 records and stores as many as 288 glucose readings over each 24-hour period.
iPro2 is adaptable to almost any patient’s lifestyle because of its small, light and water-tight profile, and the patient is not required to interact with the device. After three days of wear, the patient returns iPro2 for upload to new web-based CareLink™ iPro software, which provides a summary of glucose data in easy-to-read reports.
The system has been available in Europe for over a year and it will be great to see the impact of this technology stateside.
Flashback: Medtronic Unveils iPro 2 Professional CGM